Viking Therapeutics Opening Phase 1 Study to Evaluate Oral Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

March 28, 2023

(24/7 MARKET NEWS) – Viking Therapeutics, Inc. (NASDAQ:VKTX) announced, this morning, that it started a Phase 1 clinical study to evaluate a novel oral formulation of the company’s dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735, which is an extension of the company’s recently completed Phase 1 evaluation of subcutaneously administered VK2735 and the company believes the results from this study could be available in the second half of 2023.

Viking Therapeutics is trading at $12.63, up $3.51 (+38.49%), on 1.62 million premarket shares.

Its 52-week trading range is $2.02 to $11.985. It’s trading at new 52-week highs and is now challenging its 2018 trading price levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.